 | • レポートコード：MRC23Q35851 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、86ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の犬におけるレプトスピラ症治療市場について調査・分析し、世界の犬におけるレプトスピラ症治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（経口型、静脈注射型）、用途別セグメント分析（動物病院、動物クリニック、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Pfizer Inc.、Baxter International Inc.、Zoetic Pharmaceuticals Private Limited、Boehringer Ingelheim International GmbH、Sun Pharmaceuticals Industries Ltd.、Aurobindo Pharma、King Pharmaceuticals、Hikma Pharmaceuticals PLC、Almirall LLC.、Fresenius Kabi USA、Tolmar Pharmaceuticals, Inc.、Mayne Pharma Group Limitedなどが含まれています。世界の犬におけるレプトスピラ症治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、犬におけるレプトスピラ症治療市場規模を推定する際に考慮しました。本レポートは、犬におけるレプトスピラ症治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、犬におけるレプトスピラ症治療に関するビジネス上の意思決定に役立てることを目的としています。 ・犬におけるレプトスピラ症治療市場の概要 - 犬におけるレプトスピラ症治療のタイプ別セグメント - 世界の犬におけるレプトスピラ症治療市場規模：タイプ別分析（経口型、静脈注射型） - 犬におけるレプトスピラ症治療の用途別セグメント - 世界の犬におけるレプトスピラ症治療市場規模：用途別分析（動物病院、動物クリニック、その他） - 世界の犬におけるレプトスピラ症治療市場規模予測（2018年-2029年） ・犬におけるレプトスピラ症治療市場の成長トレンド - 犬におけるレプトスピラ症治療の地域別市場規模（2018年-2029年） - 犬におけるレプトスピラ症治療市場ダイナミクス - 犬におけるレプトスピラ症治療の業界動向 - 犬におけるレプトスピラ症治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：経口型、静脈注射型 - 世界の犬におけるレプトスピラ症治療のタイプ別市場規模（2018年-2023年） - 世界の犬におけるレプトスピラ症治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：動物病院、動物クリニック、その他 - 世界の犬におけるレプトスピラ症治療の用途別市場規模（2018年-2023年） - 世界の犬におけるレプトスピラ症治療の用途別市場規模（2024年-2029年） ・犬におけるレプトスピラ症治療の地域別市場規模 - 北米の犬におけるレプトスピラ症治療市場規模（2018年-2029年） - アメリカの犬におけるレプトスピラ症治療市場規模（2018年-2029年） - ヨーロッパの犬におけるレプトスピラ症治療市場規模（2018年-2029年） - アジア太平洋の犬におけるレプトスピラ症治療市場規模（2018年-2029年） - 中国の犬におけるレプトスピラ症治療市場規模（2018年-2029年） - 日本の犬におけるレプトスピラ症治療市場規模（2018年-2029年） - 韓国の犬におけるレプトスピラ症治療市場規模（2018年-2029年） - インドの犬におけるレプトスピラ症治療市場規模（2018年-2029年） - オーストラリアの犬におけるレプトスピラ症治療市場規模（2018年-2029年） - 中南米の犬におけるレプトスピラ症治療市場規模（2018年-2029年） - 中東・アフリカの犬におけるレプトスピラ症治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Pfizer Inc.、Baxter International Inc.、Zoetic Pharmaceuticals Private Limited、Boehringer Ingelheim International GmbH、Sun Pharmaceuticals Industries Ltd.、Aurobindo Pharma、King Pharmaceuticals、Hikma Pharmaceuticals PLC、Almirall LLC.、Fresenius Kabi USA、Tolmar Pharmaceuticals, Inc.、Mayne Pharma Group Limited ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Canine Leptospirosis Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Canine Leptospirosis Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Canine Leptospirosis Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Canine Leptospirosis Treatment in Veterinary Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Canine Leptospirosis Treatment include Pfizer Inc., Baxter International Inc., Zoetic Pharmaceuticals Private Limited, Boehringer Ingelheim International GmbH, Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma, King Pharmaceuticals, Hikma Pharmaceuticals PLC and Almirall LLC., etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Canine Leptospirosis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Canine Leptospirosis Treatment.
The Canine Leptospirosis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Canine Leptospirosis Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Canine Leptospirosis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer Inc.
Baxter International Inc.
Zoetic Pharmaceuticals Private Limited
Boehringer Ingelheim International GmbH
Sun Pharmaceuticals Industries Ltd.
Aurobindo Pharma
King Pharmaceuticals
Hikma Pharmaceuticals PLC
Almirall LLC.
Fresenius Kabi USA
Tolmar Pharmaceuticals, Inc.
Mayne Pharma Group Limited
Segment by Type
Oral
Intravenous Injection
Segment by Application
Veterinary Hospital
Veterinary Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Canine Leptospirosis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Canine Leptospirosis Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oral
1.2.3 Intravenous Injection
1.3 Market by Application
1.3.1 Global Canine Leptospirosis Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Veterinary Hospital
1.3.3 Veterinary Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Canine Leptospirosis Treatment Market Perspective (2018-2029)
2.2 Canine Leptospirosis Treatment Growth Trends by Region
2.2.1 Global Canine Leptospirosis Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Canine Leptospirosis Treatment Historic Market Size by Region (2018-2023)
2.2.3 Canine Leptospirosis Treatment Forecasted Market Size by Region (2024-2029)
2.3 Canine Leptospirosis Treatment Market Dynamics
2.3.1 Canine Leptospirosis Treatment Industry Trends
2.3.2 Canine Leptospirosis Treatment Market Drivers
2.3.3 Canine Leptospirosis Treatment Market Challenges
2.3.4 Canine Leptospirosis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Canine Leptospirosis Treatment Players by Revenue
3.1.1 Global Top Canine Leptospirosis Treatment Players by Revenue (2018-2023)
3.1.2 Global Canine Leptospirosis Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Canine Leptospirosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Canine Leptospirosis Treatment Revenue
3.4 Global Canine Leptospirosis Treatment Market Concentration Ratio
3.4.1 Global Canine Leptospirosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Canine Leptospirosis Treatment Revenue in 2022
3.5 Canine Leptospirosis Treatment Key Players Head office and Area Served
3.6 Key Players Canine Leptospirosis Treatment Product Solution and Service
3.7 Date of Enter into Canine Leptospirosis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Canine Leptospirosis Treatment Breakdown Data by Type
4.1 Global Canine Leptospirosis Treatment Historic Market Size by Type (2018-2023)
4.2 Global Canine Leptospirosis Treatment Forecasted Market Size by Type (2024-2029)
5 Canine Leptospirosis Treatment Breakdown Data by Application
5.1 Global Canine Leptospirosis Treatment Historic Market Size by Application (2018-2023)
5.2 Global Canine Leptospirosis Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Canine Leptospirosis Treatment Market Size (2018-2029)
6.2 North America Canine Leptospirosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Canine Leptospirosis Treatment Market Size by Country (2018-2023)
6.4 North America Canine Leptospirosis Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Canine Leptospirosis Treatment Market Size (2018-2029)
7.2 Europe Canine Leptospirosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Canine Leptospirosis Treatment Market Size by Country (2018-2023)
7.4 Europe Canine Leptospirosis Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Canine Leptospirosis Treatment Market Size (2018-2029)
8.2 Asia-Pacific Canine Leptospirosis Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Canine Leptospirosis Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Canine Leptospirosis Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Canine Leptospirosis Treatment Market Size (2018-2029)
9.2 Latin America Canine Leptospirosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Canine Leptospirosis Treatment Market Size by Country (2018-2023)
9.4 Latin America Canine Leptospirosis Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Canine Leptospirosis Treatment Market Size (2018-2029)
10.2 Middle East & Africa Canine Leptospirosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Canine Leptospirosis Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Canine Leptospirosis Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Detail
11.1.2 Pfizer Inc. Business Overview
11.1.3 Pfizer Inc. Canine Leptospirosis Treatment Introduction
11.1.4 Pfizer Inc. Revenue in Canine Leptospirosis Treatment Business (2018-2023)
11.1.5 Pfizer Inc. Recent Development
11.2 Baxter International Inc.
11.2.1 Baxter International Inc. Company Detail
11.2.2 Baxter International Inc. Business Overview
11.2.3 Baxter International Inc. Canine Leptospirosis Treatment Introduction
11.2.4 Baxter International Inc. Revenue in Canine Leptospirosis Treatment Business (2018-2023)
11.2.5 Baxter International Inc. Recent Development
11.3 Zoetic Pharmaceuticals Private Limited
11.3.1 Zoetic Pharmaceuticals Private Limited Company Detail
11.3.2 Zoetic Pharmaceuticals Private Limited Business Overview
11.3.3 Zoetic Pharmaceuticals Private Limited Canine Leptospirosis Treatment Introduction
11.3.4 Zoetic Pharmaceuticals Private Limited Revenue in Canine Leptospirosis Treatment Business (2018-2023)
11.3.5 Zoetic Pharmaceuticals Private Limited Recent Development
11.4 Boehringer Ingelheim International GmbH
11.4.1 Boehringer Ingelheim International GmbH Company Detail
11.4.2 Boehringer Ingelheim International GmbH Business Overview
11.4.3 Boehringer Ingelheim International GmbH Canine Leptospirosis Treatment Introduction
11.4.4 Boehringer Ingelheim International GmbH Revenue in Canine Leptospirosis Treatment Business (2018-2023)
11.4.5 Boehringer Ingelheim International GmbH Recent Development
11.5 Sun Pharmaceuticals Industries Ltd.
11.5.1 Sun Pharmaceuticals Industries Ltd. Company Detail
11.5.2 Sun Pharmaceuticals Industries Ltd. Business Overview
11.5.3 Sun Pharmaceuticals Industries Ltd. Canine Leptospirosis Treatment Introduction
11.5.4 Sun Pharmaceuticals Industries Ltd. Revenue in Canine Leptospirosis Treatment Business (2018-2023)
11.5.5 Sun Pharmaceuticals Industries Ltd. Recent Development
11.6 Aurobindo Pharma
11.6.1 Aurobindo Pharma Company Detail
11.6.2 Aurobindo Pharma Business Overview
11.6.3 Aurobindo Pharma Canine Leptospirosis Treatment Introduction
11.6.4 Aurobindo Pharma Revenue in Canine Leptospirosis Treatment Business (2018-2023)
11.6.5 Aurobindo Pharma Recent Development
11.7 King Pharmaceuticals
11.7.1 King Pharmaceuticals Company Detail
11.7.2 King Pharmaceuticals Business Overview
11.7.3 King Pharmaceuticals Canine Leptospirosis Treatment Introduction
11.7.4 King Pharmaceuticals Revenue in Canine Leptospirosis Treatment Business (2018-2023)
11.7.5 King Pharmaceuticals Recent Development
11.8 Hikma Pharmaceuticals PLC
11.8.1 Hikma Pharmaceuticals PLC Company Detail
11.8.2 Hikma Pharmaceuticals PLC Business Overview
11.8.3 Hikma Pharmaceuticals PLC Canine Leptospirosis Treatment Introduction
11.8.4 Hikma Pharmaceuticals PLC Revenue in Canine Leptospirosis Treatment Business (2018-2023)
11.8.5 Hikma Pharmaceuticals PLC Recent Development
11.9 Almirall LLC.
11.9.1 Almirall LLC. Company Detail
11.9.2 Almirall LLC. Business Overview
11.9.3 Almirall LLC. Canine Leptospirosis Treatment Introduction
11.9.4 Almirall LLC. Revenue in Canine Leptospirosis Treatment Business (2018-2023)
11.9.5 Almirall LLC. Recent Development
11.10 Fresenius Kabi USA
11.10.1 Fresenius Kabi USA Company Detail
11.10.2 Fresenius Kabi USA Business Overview
11.10.3 Fresenius Kabi USA Canine Leptospirosis Treatment Introduction
11.10.4 Fresenius Kabi USA Revenue in Canine Leptospirosis Treatment Business (2018-2023)
11.10.5 Fresenius Kabi USA Recent Development
11.11 Tolmar Pharmaceuticals, Inc.
11.11.1 Tolmar Pharmaceuticals, Inc. Company Detail
11.11.2 Tolmar Pharmaceuticals, Inc. Business Overview
11.11.3 Tolmar Pharmaceuticals, Inc. Canine Leptospirosis Treatment Introduction
11.11.4 Tolmar Pharmaceuticals, Inc. Revenue in Canine Leptospirosis Treatment Business (2018-2023)
11.11.5 Tolmar Pharmaceuticals, Inc. Recent Development
11.12 Mayne Pharma Group Limited
11.12.1 Mayne Pharma Group Limited Company Detail
11.12.2 Mayne Pharma Group Limited Business Overview
11.12.3 Mayne Pharma Group Limited Canine Leptospirosis Treatment Introduction
11.12.4 Mayne Pharma Group Limited Revenue in Canine Leptospirosis Treatment Business (2018-2023)
11.12.5 Mayne Pharma Group Limited Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
